Is Buying Vanda Pharmaceuticals Inc. Here a Winning Strategy? Option Traders Like The Stock

 Is Buying Vanda Pharmaceuticals Inc. Here a Winning Strategy? Option Traders Like The Stock

In today’s session Vanda Pharmaceuticals Inc. (VNDA) registered an unusually high (547) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious VNDA increase. With 547 contracts traded and 76234 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: VNDA170120C00018000 closed last at: $1.1 or 12% down. The stock increased 3.58% or $0.6 on November 23, hitting $17.35. About 483,628 shares traded hands. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 83.79% since April 22, 2016 and is uptrending. It has outperformed by 78.38% the S&P500.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on February, 8. They expect $-0.07 earnings per share, up 75.00% or $0.21 from last year’s $-0.28 per share. After $0.06 actual earnings per share reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -216.67% negative EPS growth.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Out of 5 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vanda Pharmaceuticals has been the topic of 7 analyst reports since September 2, 2015 according to StockzIntelligence Inc. The company was reinitiated on Thursday, October 6 by Jefferies. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The stock has “Market Outperform” rating given by JMP Securities on Friday, August 26. On Wednesday, September 2 the stock rating was maintained by Piper Jaffray with “Buy”. On Wednesday, October 21 the stock rating was initiated by Brean Capital with “Buy”. The rating was initiated by Aegis Capital on Wednesday, November 9 with “Buy”.

According to Zacks Investment Research, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.”

Insitutional Activity: The institutional sentiment increased to 2.39 in Q2 2016. Its up 1.37, from 1.02 in 2016Q1. The ratio is positive, as 19 funds sold all Vanda Pharmaceuticals Inc. shares owned while 33 reduced positions. 19 funds bought stakes while 34 increased positions. They now own 36.20 million shares or 6.54% less from 38.73 million shares in 2016Q1.
Proshare Advsrs Lc holds 0.01% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 36,607 shares. Geode Cap Mgmt Ltd Company has 367,657 shares for 0% of their US portfolio. Rhumbline Advisers last reported 44,434 shares in the company. Blackrock Institutional Tru Na last reported 1.11M shares in the company. Voya Investment Mngmt Lc has 0% invested in the company for 18,817 shares. Ny State Common Retirement Fund has invested 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Columbus Circle reported 66,478 shares or 0.01% of all its holdings. North Star Inv Management has 5,000 shares for 0.01% of their US portfolio. Moreover, Invesco has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 12,277 shares. Legal General Grp Public Limited Com holds 0% or 6,427 shares in its portfolio. The New York-based Amici Capital Limited Liability Company has invested 0.11% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Prudential Fincl has invested 0.01% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Teachers Advisors holds 0.01% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 454,871 shares. State Street holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 1.29 million shares. The California-based Venbio Select Advisor Ltd Liability Corporation has invested 1.76% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Insider Transactions: Since September 15, 2016, the stock had 0 insider buys, and 2 sales for $27.14 million net activity. On Thursday, September 22 the insider Flynn James E sold $18.56 million.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The company has a market cap of $742.53 million. The Firm is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system disorders. It currently has negative earnings. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

VNDA Company Profile

Vanda Pharmaceuticals Inc., incorporated on November 13, 2002, is a biopharmaceutical company. The Firm is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Prnewswire.com which released: “Vanda Pharmaceuticals Settles Fanapt® Patent Litigation with Taro” on October 24, 2016, also Prnewswire.com with their article: “Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results” published on November 02, 2016, Prnewswire.com published: “Vanda Pharmaceuticals to Announce Third Quarter 2016 Financial Results on …” on October 12, 2016. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Prnewswire.com and their article: “Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results” published on July 27, 2016 as well as Prnewswire.com‘s news article titled: “Vanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial …” with publication date: December 17, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment